A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Biohit Oyj B operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 18M | 18M | 15M | 14M | 12M | 11M |
| Net Income | 0 | - | - | 2.0M | 633K | -1.8M |
| EPS | $20.38 | $20.38 | $18.37 | $0.13 | $0.04 | $-0.12 |
| Free Cash Flow | -847K | -847K | 633K | 979K | 1.9M | -524K |
| ROIC | 0.0% | 22.3% | 26.6% | 25.8% | 15.0% | -17.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.08 | 0.02 | 0.05 | 0.09 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 3.3M | 3.3M | 2.8M | 2.0M | 1.2M | -1.7M |
| Operating Margin | 18.6% | 18.6% | 17.9% | 14.0% | 10.3% | -15.8% |
| ROE | 0.0% | - | - | 22.2% | 7.7% | -19.0% |
| Shares Outstanding | 0M | - | - | 15M | 15M | 15M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 8.2M | 11M | 12M | 14M | 15M | 18M | 18M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -3.6M | -1.7M | 1.2M | 2.0M | 2.8M | 3.3M | 3.3M |
| Op. Margin | -44.6% | -15.8% | 10.3% | 14.0% | 17.9% | 18.6% | 18.6% |
| Net Income | -3.8M | -1.8M | 633K | 2.0M | N/A | N/A | 0 |
| Net Margin | -46.5% | -16.0% | 5.5% | 14.2% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -32.6% | -17.0% | 15.0% | 25.8% | 26.6% | 22.3% | 0.0% |
| ROE | -38.1% | -19.0% | 7.7% | 22.2% | N/A | N/A | 0.0% |
| ROA | -30.7% | -14.9% | 5.5% | 15.7% | N/A | N/A | 0.0% |
| Cash Flow | |||||||
| Op. Cash Flow | -29K | -524K | 1.9M | 979K | 633K | -847K | -847K |
| Free Cash Flow | -29K | -524K | 1.9M | 979K | 633K | -847K | -847K |
| Owner Earnings | -2.3M | -2.9M | 1.4M | 584K | 265K | -1.5M | -1.5M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 2.3M | 2.3M | 506K | 395K | 368K | 616K | 616K |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 2.3M | 2.3M | 506K | 395K | 368K | 616K | 616K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -1.0M | -1.1M | -2.7M | -3.1M | -3.7M | -2.6M | -4.0M |
| Cash & Equiv. | 1.2M | 1.3M | 3.4M | 3.6M | 4.0M | 4.0M | 4.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.02 | 0.02 | 0.09 | 0.05 | 0.02 | 0.08 | 0.00 |
| Interest Coverage | -18.6 | -44.8 | 3.2 | 11.5 | 7.9 | 20.9 | 20.9 |
| Equity | 10.0M | 8.6M | 7.9M | 10M | 13M | 17M | 17M |
| Total Assets | 12M | 11M | 12M | 14M | 17M | 22M | 22M |
| Total Liabilities | 2.4M | 2.7M | 3.7M | 3.8M | 3.6M | 5.5M | 5.5M |
| Intangibles | N/A | N/A | N/A | N/A | 532K | 804K | 804K |
| Retained Earnings | 2.8M | 1.2M | 1.9M | 4.2M | 7.1M | 11M | 11M |
| Working Capital | 7.3M | 8.1M | 7.4M | 9.5M | 8.6M | 6.4M | 6.4M |
| Current Assets | 9.5M | 11M | 10M | 13M | 12M | 10M | 10M |
| Current Liabilities | 2.2M | 2.5M | 3.0M | 3.3M | 3.3M | 4.1M | 4.1M |
| Per Share Data | |||||||
| EPS | -0.25 | -0.12 | 0.04 | 0.13 | 18.37 | 20.38 | 20.38 |
| Owner EPS | -0.15 | -0.19 | 0.10 | 0.04 | N/A | N/A | N/A |
| Book Value | 0.66 | 0.57 | 0.52 | 0.66 | N/A | N/A | 0.00 |
| Cash Flow/Share | -0.00 | -0.03 | 0.13 | 0.06 | N/A | N/A | 0.00 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 15.1M | 15.0M | 15.0M | 15.4M | N/A | N/A | 0.0M |
| Valuation | |||||||
| P/E Ratio | -9.7 | -18.1 | 40.8 | 16.0 | 0.1 | 0.2 | 0.1 |
| P/FCF | N/A | N/A | 13.3 | 32.8 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | 19.4 | 14.7 | -1.4 | -0.8 | -1.2 |
| Price/Book | 3.7 | 3.7 | 3.3 | 3.1 | N/A | N/A | N/A |
| Price/Sales | 4.5 | 2.9 | 2.2 | 2.3 | N/A | N/A | N/A |
| FCF Yield | -0.1% | -1.6% | 7.5% | 3.0% | N/A | N/A | N/A |
| Market Cap | 37M | 32M | 26M | 32M | 0 | 0 | 0 |
| Avg. Price | 2.89 | 2.50 | 1.69 | 2.02 | 2.28 | 3.39 | 2.27 |
| Year-End Price | 2.45 | 2.14 | 1.72 | 2.08 | 2.45 | 4.11 | 2.27 |
Biohit Oyj B passes 3 of 9 quality checks, indicating weak fundamentals.
Biohit Oyj B trades at 17.4x trailing earnings, compared to its 15-year median P/E of 8.1x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 35.7x vs a median of 23.0x. The company's 5-year average ROIC is 14.5%. At current prices, the estimated annualized return to fair value is +17.7%.
Biohit Oyj B (BIOBV-HE) has a current P/E ratio of 17.4, compared to its historical median P/E of 8.1. The stock is currently considered Fair based on its historical valuation range.
Biohit Oyj B (BIOBV-HE) has a 5-year average return on invested capital (ROIC) of 14.5%. This indicates solid capital allocation.
Biohit Oyj B (BIOBV-HE) does not currently pay a regular dividend.
Based on historical P/E analysis, Biohit Oyj B (BIOBV-HE) appears fair. The current P/E of 17.4 is 115% above its historical median of 8.1. The estimated fair value CAGR (P/E method) is 49.9%.
Biohit Oyj B (BIOBV-HE) operates in the Biotechnology industry, within the Healthcare sector.
Biohit Oyj B (BIOBV-HE) reported annual revenue of $18 million in its most recent fiscal year, based on SEC EDGAR filings.
Biohit Oyj B (BIOBV-HE) generated $-847 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Biohit Oyj B (BIOBV-HE) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
Biohit Oyj B (BIOBV-HE) reported earnings per share (EPS) of $20.38 in its most recent fiscal year.
The Ledger Terminal provides 6 years of financial data for Biohit Oyj B (BIOBV-HE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.